Company Overview and News

Portfolio Review: Continued Market Outperformance In Q1 2018

2018-04-15 seekingalpha
Integrated BioSci Investing outperformed all benchmarks since inception as we’ve compounded at the 30% rate. For the same period, the XBI, DOW, and IBB procured 27%, 15%, and 9%, respectively.
Upvote Downvote

Pipeline Concerns: Four Biotechs to Keep Your Eye On

2018-04-11 biospace
When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies. If a pipeline is not well-secured, the leaks can weaken the intrinsic value of the business.
Upvote Downvote

4 Biotech Stocks With Leaky Pipelines

2018-04-10 investorplace
When it comes to biotech stocks, a pipeline can make or break a company. Due to the nature of the clinical trial system, a company can work for years on a new drug only to have all that work disappear when a therapy is found unsafe and ineffective. This is good for the safety of healthcare, but it does introduce instability to companies.
Upvote Downvote

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

2018-04-05 zacks
If you're interested in broad exposure to the Small Cap Blend segment of the US equity market, look no further than the PowerShares DWA SmallCap Momentum Portfolio (DWAS - Free Report) , a passively managed exchange traded fund launched on 07/19/2012.
Upvote Downvote

Biotech Analysis Central Pharma News: Takeda's Potential Bid, Alkermes Setback, MediciNova Impresses

2018-04-03 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Upvote Downvote

Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session

2018-03-20 zacks
Madrigal Pharmaceuticals, Inc. (MDGL - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $113.16 –$142.90 in the past one-month time frame, witnessed a sharp increase yesterday.
Upvote Downvote

Even More Biopharma Catalysts Coming Through the End of March

2018-03-17 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
Upvote Downvote

Specialty Research: What The Lucrative NASH Market Has In Store

2018-03-16 seekingalpha
Companies with highly promising molecules include Gilead Science as well as Intercept, Enanta, and Madrigal Pharmaceuticals.
Upvote Downvote

Madrigal Pharmaceuticals: Well-Funded To Fill An Unmet Need

2018-03-13 seekingalpha
Madrigal stock is selling off today following an earnings report that showed the company burnt less money than expected.
Upvote Downvote

Immuron Achieves Positive Phase 2 NASH Results, Presents Itself As A Good Buy

2018-03-13 seekingalpha
Further testing will be needed to confirm these positive findings from the phase 2 proof of concept study, but things are looking good for Immuron.
Upvote Downvote

BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​

2018-03-13 reuters
Upvote Downvote

MDGL / Madrigal Pharmaceuticals, Inc. 10-K (Annual Report)

Use these links to rapidly review the document Table of Contents INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Upvote Downvote

Viking Tumbles On Phase 2 Trial Delay, But Remains A Solid Buy

2018-03-08 seekingalpha
Viking Therapeutics announces delay in phase 2 VK2809 data, but presents itself as a buying opportunity.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 87162T206